Cargando…

Prophylactic administration of abatacept (CTLA4-Ig; BMS-188667) prevents disease induction and bone destruction in a rat model of collagen-induced arthritis

Detalles Bibliográficos
Autores principales:	Kliwinski, C, Kukral, D, Postelnek, J, Krishnan, B, Killar, L, Nadler, S, Townsend, R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834003/ http://dx.doi.org/10.1186/ar1525

Ejemplares similares

Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes
por: Davis, PM, et al.
Publicado: (2005)

Abatacept is effective in Chinese patients with LRBA and CTLA4 deficiency
por: Yang, Lu, et al.
Publicado: (2020)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
por: Pieper, Jennifer, et al.
Publicado: (2013)

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis
por: Ruderman, Eric M, et al.
Publicado: (2005)

CTLA4-Ig Abatacept Ameliorates Proteinuria by Regulating Circulating Treg/IL-17 in Adriamycin-Induced Nephropathy Rats
por: Shuai, Lanjun, et al.
Publicado: (2020)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept)
por: Tanaka, Hiromu, et al.
Publicado: (2022)

Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis
por: Marquez Pete, Noelia, et al.
Publicado: (2020)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis
por: Jiang, Fu-Yao, et al.
Publicado: (2023)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report
por: Musabak, Ugur, et al.
Publicado: (2023)

Effects of CTLA4-Ig on human monocytes
por: Tono, Toshihiro, et al.
Publicado: (2017)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Transplant-tolerance induction by CTLA-4Ig in liver-transplanted rats: a lesson for the treatment of autoimmune diseases?
por: Fischer, U, et al.
Publicado: (2003)

CTLA4Ig Improves Murine iTreg Induction via TGFβ and Suppressor Function In Vitro
por: Pilat, Nina, et al.
Publicado: (2018)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

LPA(1) antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
por: Decato, Benjamin E., et al.
Publicado: (2022)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Abatacept treatment for rheumatoid arthritis
por: Schiff, Michael
Publicado: (2011)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model
por: Jansen, Diahann TSL, et al.
Publicado: (2015)

Functional Characterization of Human T Cell Hyporesponsiveness Induced by CTLA4-Ig
por: Rochman, Yrina, et al.
Publicado: (2015)

CTLA4-Ig treatment prevents murine experimental autoimmune encephalomyelitis
por: Cross, A.H., et al.
Publicado: (1994)

CTLA-4Ig Improves Hyperalgesia in a Mouse Model of Osteoporosis
por: Nagao, Nobuto, et al.
Publicado: (2020)

Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig
por: Kuppan, Purushothaman, et al.
Publicado: (2023)

CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment
por: Muthana, Musleh M., et al.
Publicado: (2023)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial
por: Krausz, Máté, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nu4qlqm7mgq5t78i7eq30iqimc